Summarizing the month in European dealmaking.

VC firm Oxford Bioscience's deal with Evotec gives its portfolio companies discounted access to the German biotech's screening and chemistry services--but with no obligation.

Summarizing the month in European dealmaking.

Will the emergence of new biological targets as a result of genomics and proteomics change venture investors' prejudice against diagnostics? No--or at least not until patented biomarkers can be tied more closely to the cause of the disease and to a therapeutic that treats it.